| Direct Competitor Comparison | |
|---|
| NPSP | ABT | BIIB | PVT1 | Industry |
|---|
| Market Cap: | 1.41B | 58.80B | 55.32B | N/A | 71.76B |
|---|
| Employees: | 149 | 91,000 | 5,950 | N/A | 450.00 |
|---|
| Qtrly Rev Growth (yoy): | 0.11 | 0.02 | 0.10 | N/A | 0.27 |
|---|
| Revenue (ttm):
| 108.15M | 39.97B | 5.64B | N/A | 13.93B |
|---|
| Gross Margin (ttm): | 1.00 | 0.62 | 0.90 | N/A | 0.72 |
|---|
| EBITDA (ttm): | -24.43M | 11.56B | 2.34B | N/A | 1.51B |
|---|
| Operating Margin (ttm):
| -0.24 | 0.22 | 0.35 | N/A | 0.13 |
|---|
| Net Income (ttm): | -15.97M | 6.11B | 1.50B | N/A | N/A |
|---|
| EPS (ttm): | -0.19 | 3.28 | 6.30 | N/A | 0.61 |
|---|
| P/E (ttm): | N/A | 11.50 | 36.98 | N/A | 18.43 |
|---|
| PEG (5 yr expected): | -2.13 | 1.52 | 1.54 | N/A | 1.51 |
|---|
| P/S (ttm): | 13.01 | 1.47 | 9.81 | N/A | 3.64 |
|---|
|
| ABT = Abbott Laboratories | | BIIB = Biogen Idec Inc. | | Pvt1 = Merck Serono S.A. (privately held) | | Industry = Biotechnology | |
| Biotechnology Companies Ranked By Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Amgen Inc. | AMGN | 104.53 | 0.00 | 78.39B | 17.69 |
|---|
| Genentech, Inc. | "Private" |
|---|
| Biogen Idec Inc. | BIIB | 233.07 | 0.00 | 55.32B | 36.98 |
|---|
| Genzyme Corporation | "Private" |
|---|
| Merck Serono S.A. | "Private" |
|---|
| Gilead Sciences Inc. | GILD | 55.93 | 0.00 | 85.31B | 31.32 |
|---|
| MedImmune, L.L.C. | "Private" |
|---|
| Life Technologies Corporation | LIFE | 74.10 | 0.00 | 12.75B | 31.37 |
|---|
| Teva Pharmaceutical Industries Limited | TEVA | 39.35 | 0.00 | 33.53B | 19.65 |
|---|
| Sandoz International GmbH | "Private" |
|---|
|
| Generic Drugmakers Ranked by Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Actavis, Inc. | ACT | 130.04 | 0.00 | 16.61B | N/A |
|---|
| Ranbaxy Laboratories Limited | "Private" |
|---|
| Mylan, Inc. | MYL | 31.55 | 0.00 | 12.02B | 21.08 |
|---|
| Pfizer Inc. | PFE | 29.30 | 0.00 | 207.83B | 14.03 |
|---|
| Johnson & Johnson | JNJ | 88.46 | 0.00 | 248.47B | 24.02 |
|---|
| GlaxoSmithKline plc | GSK | 52.94 | 0.00 | 128.22B | 19.35 |
|---|
| Sanofi | SNY | 55.05 | 0.00 | 145.70B | 27.13 |
|---|
| Novartis AG | NVS | 74.62 | 0.00 | 183.36B | 18.94 |
|---|
| Roche Holding AG | RHHBY | 65.65 | 0.00 | 222.81B | 21.97 |
|---|
| AstraZeneca PLC | AZN | 52.35 | 0.00 | 65.44B | 11.58 |
|---|
|
| Drugmakers Ranked By Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Abbott Laboratories | ABT | 37.72 | 0.00 | 58.80B | 11.50 |
|---|
| Bristol-Myers Squibb Company | BMY | 46.40 | 0.00 | 76.21B | 52.55 |
|---|
|
| News on Direct Competitors | |
|---|
- ABT
- CE Mark for Abbott's Xience Xpedition 48 Zacks Wed 6:05pm
- BIIB
- Biogen Idec Submits Application to FDA for Approval of PLEGRIDY™ (Peginterferon Beta-1a) in Multiple Sclerosis Business Wire Tue, May 21
- BIIB
- FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor VIII Therapy for Hemophilia A Business Wire Mon, May 13
- ABT
- BSX, ABT, ZMH, and ETRM Under StockCall’s Microscope Accesswire Thu, May 2
- BIIB
- Exclusive: Royalty Pharma considers sweetened deal for Elan - sources Reuters Thu, Apr 11
- BIIB
- The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of Daclizumab HYP in Multiple Sclerosis Business Wire Thu, Apr 4
- BIIB
- Biogen Idec Completes Purchase of Full Rights and Control of TYSABRI® Business Wire Tue, Apr 2
- ABT
- Analysis: Big Pharma down, not out, after Indian patent blow Reuters Tue, Apr 2
- ABT
- AbbVie seeks to stop EU agency releasing drug data Reuters Sun, Mar 10
- ABT
- News Recap: Google Inc, Pacwest Equities Inc, Abbott Laboratories, eBay Inc, Clearwire Corporation Accesswire Thu, Oct 18
All headlines for these symbols... Currency in USD. | |
|
0.08%